Chlor Alkali
Epigral’s chlor-alkali operations produce chlorine, caustic soda, and hydrogen from sodium chloride.

Epigral is an Indian chemical manufacturer of chlor-alkali products, chloromethanes, epichlorohydrin, and CPVC resin and compound.
epigral.comCrawled Nov 17, 2026
Epigral’s chlor-alkali operations produce chlorine, caustic soda, and hydrogen from sodium chloride.
Epigral’s chloromethanes plant produces methyl chloride, methylene dichloride, chloroform, and carbon tetrachloride for pharmaceuticals, refrigerants, and agrochemicals.
Epigral offers CPVC resin and compound for heat-resistant, durable piping applications.
Epigral produces epichlorohydrin from renewable glycerin, supporting sustainable chemical manufacturing.
Epigral manufactures hydrogen peroxide via the anthraquinone process.
Epigral enters the chlorotoluene value chain to develop specialty chemicals and import-substitute products.
Print Chronicles highlights Epigral’s media coverage in credible publications.
Epigral emphasizes sustainable practices, environmental health, and employee well-being in its culture.
Epigral’s Board of Directors guides the company’s direction with transparency and responsible decision-making.
Epigral holds certifications in quality management, environmental responsibility, and safety standards.
Home / Investors / Governance, Policies & Compliances Corporate Governance Report FY 2026-27 Corporate Governance Report – 30.06.2026 FY 2025-26 Corporate Governance Report – 31.03.2026Corporate Governance Report – 31.12.2025Corporate Governance Report – 30.09.2025Corporate Governance Report – 30.06.2025 FY 2024-25 Corporate Governance Report – 31.03.2025Corporate Governance Report – 31.12.2024Corporate Governance Report – 30.09.2024Corporate Governance Report –
The page provides shareholder information, including investor conferences, analyst meetings, and transcripts.
The page outlines Epigral’s ratings rationale from 2021 to 2026.
Home / Investors / Shareholding Pattern FY 2026-27 As on 30-06-2026Shareholding Pattern Report 30.06.2026 FY 2025-26 As on 31-03-2026Shareholding Pattern Report 31.03.2026 As on 30-06-2025Shareholding Pattern Report 30.06.2025As on 31-12-2025Shareholding Pattern Report 31.12.2025As on 30-09-2025Shareholding Pattern Report 30.09.2025 FY 2024-25 As on 31-03-2025Shareholding Pattern Report 31.03.2025 As on 30-06-2024Shareholding Pattern Report 30.06.2024As on 31-12-2024Shareholding Pattern Report 3
The page provides Epigral’s registered office address, phone, fax, and email.
The page answers questions about Epigral’s incorporation date and fiscal year.
The page lists investor grievance contacts, including the company secretary and registrar details.
Epigral, an Ahmedabad-based chemical manufacturer, aims for ₹3,000 crore in revenue for FY27, driven by stronger second-half performance. The company anticipates higher volume growth in the third and fourth quarters, boosting overall financial results.
Epigral reports a **26% increase in Q2 FY27 profit after tax (PAT) to Rs 64 crore**, driven by **28% revenue growth to Rs 752 crore**. The company cites higher raw material costs as a factor in declining profit margins. Management announces plans for further expansion.
Epigral, a specialty chemicals manufacturer, aims for ₹5,000 crore in revenue by FY31 (2030-31) through planned expansions in CPVC Resin and Epichlorohydrin (ECH) production. The company’s growth strategy relies on increasing manufacturing capacity to meet demand. A senior executive highlighted these scale-ups as key drivers for the ambitious financial target.
Epigral is adding **125,000 tonnes per annum (TPA) of epoxy resin production** at its Dahej facility to meet rising demand for epoxy-based specialty chemicals. The expansion targets operations beginning in the **second half of FY2028**, scaling the company’s capacity in response to market growth. The project reinforces Epigral’s focus on high-demand chemical solutions for industrial applications.
Epigral’s stock rises 15% after reporting record fourth-quarter revenue. The company faces profit challenges despite strong sales growth, as operational pressures weigh on margins.